Source: Eur Respir J, 52 (2) 1801025; 10.1183/13993003.01025-2018
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
David J. Allen, Leanne-Jo Holmes, Kerry A. Hince, Rachael Daly, Calra Ustabashi, Gael Tavernier. Nonadherence with inhaled preventer therapy in severe asthmatic patients on long-term omalizumab. Eur Respir J, 52 (2) 1801025; 10.1183/13993003.01025-2018

Member's Comments

No comment yet.

Related content which might interest you: Step-up therapy for children with uncontrolled asthma receiving inhaled corticosteroids Source: Breathe 2010; 6: 365 Year: 2010 Inhaled antibiotic therapy in patients with severe asthma Source: Virtual Congress 2021 – Advances in asthma treatment Year: 2021 Patients with moderate asthma symptoms may benefit from short-term inhaled corticosteroid monotherapy Source: Eur Respir J 2007; 30: Suppl. 51, 615s Year: 2007 Switching asthma patients using high-dose inhaled steroids to budesonide/formoterol maintenance and reliever therapy Source: Annual Congress 2010 - Management of airway disease Year: 2010 Real-life long-term omalizumab therapy in children with severe allergic asthma Source: Eur Respir J 2015; 46: 856-859 Year: 2015 Adherence to corticosteroids and clinical outcomes in mepolizumab therapy for severe asthma Source: Eur Respir J, 55 (5) 1902259; 10.1183/13993003.02259-2019 Year: 2020 Low adherence to inhaled corticosteroids/long-acting ß2-agonists and biologic treatment in severe asthmatics Source: ERJ Open Res, 6 (2) 00017-2020; 10.1183/23120541.00017-2020 Year: 2020 The effects of nebulised bronchodilators and corticosteroids treatment compared with inhaled drug therapy for moderate COPD patients Source: Eur Respir J 2004; 24: Suppl. 48, 290s Year: 2004 Discontinuation of inhaled corticosteroid treatment in patients with COPD diagnosed in general practice Source: Eur Respir J 2002; 20: Suppl. 38, 212s Year: 2002 Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010 Efficacy and safety of high-dose inhaled corticosteroids therapy in children with asthma Source: Annual Congress 2010 - Allergy and risk factors in paediatrics Year: 2010 The effectiveness of omalizumab in steroid-dependent asthma patients Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 Adding omalizumab to high-dose ICS and LABA significantly improves quality of life in patients with severe persistent allergic asthma Source: Eur Respir J 2006; 28: Suppl. 50, 440s Year: 2006 Does adherence to ICS/LABA therapy affect response to mepolizumab in the treatment of severe asthma? Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Anti-IgE therapy with omalizumab decreases exacerbations in patients with poorly controlled moderate-to-severe allergic asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003 Long-term adherence to inhaled corticosteroids and asthma control in adult-onset asthma Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Bronchodilator reversibility and short-term inhaled corticosteroid response in Japanese patients with COPD Source: Eur Respir J 2004; 24: Suppl. 48, 341s Year: 2004 The efficacy of omalizumab in severe in asthma after treatment withdrawal Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Osteoporosis in patients with long-term inhaled corticosteroids treatment Source: Eur Respir J 2007; 30: Suppl. 51, 613s Year: 2007 Cessation of long-acting beta2-agonist in children with persistent asthma on inhaled corticosteroids Source: Eur Respir J 2016; 48: 558-560 Year: 2016